Medullary Thyroid Cancer: RET Mutation, Calcitonin Surveillance, and Selpercatinib Therapy

Endocrine Oncology · Targeted Therapy

Medullary Thyroid Cancer: RET Mutation, Calcitonin Surveillance, and Selpercatinib Therapy

Parafollicular C-cell origin, sporadic versus hereditary disease, MEN2A and MEN2B syndrome recognition, calcitonin and CEA biomarker surveillance, total thyroidectomy with central neck dissection, and the transformative role of RET-selective tyrosine kinase inhibitors selpercatinib and pralsetinib.

Author: gomdori, MD Specialty: Endocrinology & Endocrine Oncology Reading time: 22 minutes

Executive Summary

Medullary thyroid cancer (MTC) accounts for 1–2% of thyroid cancers but a disproportionate share of thyroid cancer mortality because of distinct biology — it arises from parafollicular C-cells rather than thyroid follicular cells, does not concentrate iodine, and is unresponsive to radioactive iodine therapy. Approximately 75% of MTC is sporadic; 25% is hereditary as part of multiple endocrine neoplasia type 2 (MEN2). MEN2A combines MTC with pheochromocytoma and primary hyperparathyroidism; MEN2B presents earlier and more aggressively with MTC, pheochromocytoma, mucosal neuromas, marfanoid habitus, and intestinal ganglioneuromatosis. Both arise from gain-of-function germline RET proto-oncogene mutations, while approximately 50% of sporadic MTC harbors somatic RET mutations (most commonly M918T) and another 10–25% carries RAS mutations. Calcitonin and carcinoembryonic antigen (CEA) are highly sensitive serum biomarkers with critical roles in screening, staging, and surveillance — calcitonin doubling time correlates strongly with prognosis. Total thyroidectomy with prophylactic central neck (level VI) dissection is standard, with lateral neck dissection guided by imaging or calcitonin level (consider if >200 pg/mL). Prophylactic thyroidectomy is recommended for MEN2 carriers based on RET mutation risk category: highest-risk (M918T, MEN2B) before age 1, high-risk (MEN2A C634, A883F) by age 5, moderate-risk by age 5 or by calcitonin and ultrasound monitoring. Pheochromocytoma must be excluded biochemically before any neck surgery. For metastatic or progressive disease, RET-selective tyrosine kinase inhibitors selpercatinib (160 mg PO BID) and pralsetinib (400 mg PO daily) achieve objective response rates of 60–73% — a paradigm shift from earlier multi-targeted TKIs vandetanib and cabozantinib, which had higher toxicity. Surveillance combines calcitonin and CEA every 3–6 months, neck ultrasound, and cross-sectional imaging stratified by biochemical recurrence and doubling times.

1–2%
of Thyroid Cancers
25%
Hereditary (MEN2)
60–73%
RET-TKI Response Rate
<6 mo
High-Risk Calcitonin Doubling Time

Pathophysiology and C-Cell Biology

Parafollicular C-cells (also called C-cells or calcitonin cells) derive embryologically from the neural crest, migrating into the ultimobranchial bodies and ultimately settling in the upper and middle thirds of the thyroid lobes. They constitute less than 1% of thyroid cells but produce calcitonin in response to elevated serum calcium — a physiologic role that is largely vestigial in adults but is exploited as a tumor marker in MTC. C-cell distribution explains why MTC characteristically arises in the upper lateral aspects of the thyroid lobes and why bilateral disease is common.

RET Proto-Oncogene Signaling

RET (REarranged during Transfection) encodes a receptor tyrosine kinase activated by GDNF family ligands (GDNF, neurturin, artemin, persephin) bound to GFRα co-receptors. Ligand binding triggers RET dimerization, autophosphorylation, and downstream activation of RAS-MAPK and PI3K-AKT pathways driving proliferation and survival. Gain-of-function germline RET mutations cause constitutive activation and underlie MEN2 syndromes; somatic RET mutations (most commonly M918T) drive about 50% of sporadic MTC. The therapeutic relevance is direct — selpercatinib and pralsetinib are highly selective RET inhibitors with activity against both germline and somatic RET-mutant MTC.

Sporadic vs Hereditary Patterns

FeatureSporadic MTC (~75%)Hereditary MTC (~25%)
Age at presentation40–60 yearsChildren to young adults
Tumor distributionUnifocal, unilateral typicalMultifocal, bilateral typical
RET mutationSomatic (M918T 40%; others)Germline (codon-specific)
Family historyAbsentFamily screening positive
Associated tumorsNone typicalPheochromocytoma, parathyroid hyperplasia
Genetic testingTumor-onlyGermline blood test mandatory at diagnosis

All MTC patients — even those without family history — should undergo germline RET mutation testing, because de novo germline mutations occur (especially MEN2B M918T, where 50% of cases are de novo without family history) and identification has profound implications for family screening.

Medullary Thyroid Cancer — Thyroid Anatomy Thyroid gland anatomy with nodule locations Medullary Thyroid Cancer — Thyroid Anatomy Trachea Right Lobe Left Lobe Isthmus Bethesda System (FNA Cytology) Bethesda I: Non-diagnostic Bethesda II: Benign Bethesda III: AUS/FLUS Bethesda IV: Follicular neoplasm Bethesda V: Suspicious Bethesda VI: Malignant
Medullary Thyroid Cancer — Thyroid Anatomy

MEN2A, MEN2B, and FMTC

Hereditary MTC clusters into three phenotypes — MEN2A (~80% of MEN2), MEN2B (~5%), and familial MTC (FMTC, classified within MEN2A in current nomenclature). The American Thyroid Association classifies RET mutations into highest, high, and moderate risk categories that guide age of prophylactic thyroidectomy.

MEN2A

  • MTC: nearly 100% penetrance by adulthood; usually multifocal bilateral
  • Pheochromocytoma: 50% lifetime risk; bilateral in 50%; typically benign; predominantly epinephrine secreting
  • Primary hyperparathyroidism: 20–30% (usually mild, multigland hyperplasia)
  • Hirschsprung disease: rare, in some families with specific RET mutations
  • Cutaneous lichen amyloidosis: intrascapular pruritic lichenoid rash

MEN2B

  • MTC: 100% penetrance, earliest age of onset (often before age 5), most aggressive; often metastatic at diagnosis
  • Pheochromocytoma: 50% risk; often bilateral
  • Mucosal neuromas: tongue, lips, conjunctiva — pathognomonic; visible from infancy
  • Marfanoid habitus: tall thin build, long extremities, joint hyperflexibility (without lens or aortic disease of true Marfan)
  • Intestinal ganglioneuromatosis: chronic constipation, megacolon
  • Absent primary hyperparathyroidism

RET Risk Stratification (ATA 2015)

Risk CategoryMutationsPhenotypeProphylactic Thyroidectomy
Highest (HST)M918T (codon 918)MEN2BWithin first year of life (ideally first months)
High (H)C634, A883FMEN2A classicBefore age 5
Moderate (MOD)Most other codons (e.g., 609, 611, 618, 620, 768, 790, 804, 891)MEN2A milder, FMTCBy age 5 or based on calcitonin and ultrasound
Pheochromocytoma First — Always Before any thyroid surgery in MEN2 carriers, pheochromocytoma must be excluded biochemically (plasma free metanephrines and normetanephrines, 24-hour urinary fractionated metanephrines). Operating on an unrecognized pheochromocytoma — anesthesia stress and surgical manipulation — can precipitate fatal hypertensive crisis. Pheochromocytoma resection with appropriate alpha- and beta-blockade preceding it precedes thyroidectomy. Annual biochemical surveillance starts at age 11 for high-risk and age 16 for moderate-risk MEN2A.

Diagnosis: Calcitonin, CEA, Biopsy

MTC is most often diagnosed during workup of a thyroid nodule or — less commonly now — during family screening of MEN2 carriers. Calcitonin and CEA are the cornerstones of biochemical diagnosis and surveillance.

Calcitonin

Basal serum calcitonin is elevated in nearly all clinically apparent MTC. Reference ranges differ by sex (men <14 pg/mL, women <5 pg/mL with most assays). Levels >100 pg/mL strongly suggest MTC; values 20–100 pg/mL warrant further evaluation including stimulation testing (calcium or pentagastrin where available) and FNA. Routine calcitonin measurement in all thyroid nodules remains controversial in the U.S. (American Thyroid Association considers it optional with weak recommendation) but is standard practice in much of Europe given downstream prognostic value.

CEA

CEA is non-specific (also elevated in colorectal, pancreatic, lung, and breast cancers and smoking) but is a valuable secondary marker. CEA is particularly useful when calcitonin doubling time becomes faster than CEA doubling time — paradoxically suggesting C-cell dedifferentiation with worse prognosis. Both markers should be tracked together throughout surveillance.

FNA Cytology

FNA may show classic MTC features — spindle to plasmacytoid cells, eccentric nuclei with salt-and-pepper chromatin, amyloid stroma (Congo red positive), absent thyroglobulin staining, positive calcitonin and CEA immunohistochemistry. However, FNA cytology alone has lower sensitivity for MTC than for papillary thyroid cancer. Calcitonin measurement in FNA washout fluid markedly increases sensitivity and should be requested when MTC is suspected. Bethesda cytology categorization may misclassify MTC as suspicious for malignancy or follicular neoplasm.

Pre-operative Workup

TestIndicationNotes
Plasma metanephrinesAll MEN2; sporadic MTC at diagnosisExclude pheochromocytoma BEFORE surgery
PTH and calciumAll MEN2AIdentify primary hyperparathyroidism
Serum calcitonin and CEAAll MTCBaseline for postoperative comparison
RET germline testAll MTC patientsEven sporadic appearance — de novo mutations occur
Neck ultrasoundAll MTCBilateral lobes + central + lateral compartments
CT chest, neck, abdomenCalcitonin >500 pg/mL or imaging-positive nodesExclude liver, lung, mediastinal, bone metastases
Ga-68 DOTATATE PETDetection of distant diseaseHigher sensitivity than CT for distant nodal/skeletal disease in some cases
FDG-PETCalcitonin doubling <1 year, aggressive phenotypePositive FDG correlates with worse prognosis
Medullary Thyroid Cancer — Procedure Steps Surgical stepper: Medullary Thyroid Cancer — Procedure Steps Medullary Thyroid Cancer — Procedure Steps 1 Diagnosis Calcitonin (>100 pg/mL strongly suggestive); CEA; thyroid US + FNA; pheochromocytoma rule out 2 Genetic counseling All MTC patients: RET germline testing; cascade testing of family if positive 3 Surgery Total thyroidectomy + central neck dissection; lateral neck dissection if biopsy-proven 4 Pheochromocytoma rule out BEFORE thyroid surgery in any RET+ patient: plasma metanephrines + adrenal imaging 5 Surveillance Calcitonin + CEA q3-6 mo first 2 yr, then annually; doubling time predicts progression 6 Advanced disease Selpercatinib 160mg PO BID for RET+ (most MTC); cabozantinib alternative; vandetanib
Medullary Thyroid Cancer — Procedure Steps

Surgical Management

Surgery is the cornerstone of curative MTC therapy. Because MTC does not concentrate iodine and does not respond to radioactive iodine, complete surgical removal of macroscopic disease is essential; missed lymph nodes drive biochemical and structural recurrence. The principles are total thyroidectomy with prophylactic central neck dissection plus selective lateral neck dissection guided by imaging and calcitonin.

Total Thyroidectomy

Total thyroidectomy is standard for all MTC. Bilateral disease occurs in nearly all hereditary cases and 30% of “sporadic” cases (some of which are unrecognized hereditary), making lobectomy inadequate. The recurrent laryngeal nerves and parathyroid glands are identified and preserved. In MEN2A patients with primary hyperparathyroidism, abnormal parathyroid glands are removed at the same operation; normal glands may be auto-transplanted to forearm muscle in case of bilateral abnormalities.

Central Neck Dissection (Level VI)

Prophylactic central neck dissection (level VI) — the compartment between the hyoid bone, suprasternal notch, and carotid sheaths — is recommended for all MTC at initial surgery because micrometastases in this compartment are common (40–80%) even when ultrasound is negative. Performing it at index surgery has lower morbidity than reoperative central neck surgery (which carries higher rates of recurrent laryngeal nerve injury and hypoparathyroidism).

Lateral Neck Dissection (Levels II–V)

IndicationRecommendation
Imaging-confirmed lateral nodesTherapeutic lateral neck dissection on the affected side
Basal calcitonin >200 pg/mLConsider prophylactic ipsilateral lateral neck dissection
Basal calcitonin >500 pg/mLConsider bilateral prophylactic lateral neck dissection
Locally advanced primary tumor (T4)Bilateral lateral neck dissection

Prophylactic Thyroidectomy in MEN2 Carriers

For MEN2 carriers identified by family screening, prophylactic thyroidectomy is the only definitive way to prevent MTC. Timing depends on RET mutation risk category:

  • Highest risk (M918T, MEN2B): within the first year of life — many recommend by 6 months. C-cell hyperplasia and microscopic MTC may already be present
  • High risk (C634, A883F): before age 5, often around age 3–4
  • Moderate risk: by age 5 if calcitonin is elevated or ultrasound is suspicious; may defer with annual calcitonin surveillance until elevation

Central neck dissection is added if pre-operative calcitonin is elevated or if imaging shows nodes; in some moderate-risk pediatric patients with normal calcitonin and imaging, total thyroidectomy alone is acceptable to minimize parathyroid and recurrent laryngeal nerve injury.

Postoperative Thyroid Hormone Replacement

After total thyroidectomy, lifelong levothyroxine is required at 1.6 mcg/kg/day PO typical dose. Unlike differentiated thyroid cancer, TSH suppression below normal is NOT required — MTC C-cells are not TSH-responsive. Target TSH is mid-normal range. Titrate by measuring TSH 6–8 weeks after starting/changing dose.

Systemic Therapy and TKIs

Systemic therapy is reserved for unresectable, metastatic, or rapidly progressive MTC. Because MTC is a slow-growing tumor in many patients, watchful waiting is appropriate when calcitonin doubling time is >2 years and disease burden is stable. Systemic therapy is initiated when there is structural progression on imaging, rapid calcitonin or CEA doubling (<6–12 months), symptoms, or threatened structures.

RET-Selective TKIs (First-Line)

Two highly selective RET kinase inhibitors received FDA approval based on objective response rates of 60–73% and durable disease control:

DrugStandard DoseIndicationKey Toxicities
Selpercatinib (Retevmo)160 mg PO BID if ≥50 kg; 120 mg PO BID if <50 kgRET-mutant MTCHTN, transaminitis, QTc prolongation, hemorrhage, hypersensitivity
Pralsetinib (Gavreto)400 mg PO daily on empty stomachRET-mutant MTCHTN, fatigue, transaminitis, pneumonitis, neutropenia

Selpercatinib has a slight edge in tolerability and is more commonly used first; both are appropriate first-line. Treatment is continuous until progression or unacceptable toxicity. Drug interactions are clinically relevant — selpercatinib is metabolized by CYP3A4 and is a P-gp/BCRP substrate; coadministration with strong CYP3A4 inhibitors or inducers requires dose adjustment. Both drugs require periodic ECG (QTc), liver function tests, blood pressure monitoring, and CBC.

Multi-Targeted TKIs (Pre-RET-Selective Era)

DrugDoseNotes
Vandetanib (Caprelsa)300 mg PO dailyFDA-approved 2011 for advanced MTC; QTc prolongation BBW; REMS program required
Cabozantinib (Cometriq)140 mg PO daily empty stomach (capsule formulation for MTC)FDA-approved 2012; significant GI and skin toxicity; HTN; bleeding

Both predate the RET-selective era and have higher toxicity. They retain a role for RET-mutation-negative MTC (where selpercatinib/pralsetinib have less activity), after RET-selective TKI failure (acquired resistance mutations), or where access to RET-selective TKIs is limited. Both have shown progression-free survival benefit but no proven overall survival benefit in pivotal trials.

Other Systemic Options

  • External beam radiotherapy: for unresectable locoregional disease, painful bone metastases, or brain metastases
  • Bisphosphonates or denosumab: for bone-dominant disease and skeletal-related events
  • Liver-directed therapy (TACE, radioembolization): selected oligometastatic hepatic disease
  • Cytotoxic chemotherapy: dacarbazine-based regimens have minimal activity; rarely used in TKI era
  • Peptide-receptor radionuclide therapy (PRRT) with Lu-177 DOTATATE: investigational for somatostatin-receptor-positive MTC
When to Refer to Endocrine Oncology / Multidisciplinary Tumor Board All metastatic, recurrent, or rapidly progressive MTC should be discussed at a thyroid cancer multidisciplinary tumor board with endocrine oncology, surgical oncology, and pathology input. Decisions about timing and choice of TKI, role of locoregional therapy, and surveillance cadence benefit from coordinated review. Refer immediately for: calcitonin doubling <1 year, structural progression on serial imaging, biopsy-proven distant metastases, or persistent post-thyroidectomy calcitonin >500 pg/mL.

Surveillance, Special Populations, FAQ

Postoperative surveillance is biomarker-driven and stratified by biochemical response.

Postoperative Surveillance Schedule

StatusCalcitonin and CEA FrequencyImaging
Biochemical cure (calcitonin undetectable post-op)Every 6–12 monthsAnnual neck US; CT/MRI if symptomatic
Biochemical incomplete response (detectable but stable calcitonin)Every 3–6 months; monitor doubling timeNeck US every 6–12 months; cross-sectional if calcitonin trend rises
Calcitonin >150 pg/mLEvery 3 monthsCT chest/abdomen/pelvis; bone imaging; consider DOTATATE PET
Structural recurrence or metastaticEvery 3 monthsCross-sectional imaging every 3–6 months; functional imaging as indicated

Calcitonin Doubling Time Prognostic Tiers

  • Doubling time >2 years: indolent course; observation often appropriate
  • Doubling time 6 months to 2 years: intermediate; intensify imaging and consider therapy
  • Doubling time <6 months: aggressive; initiate systemic therapy

Special Populations

Pregnancy: selpercatinib and pralsetinib are teratogenic — strict contraception required. Pregnancy after MTC treatment is feasible after biochemical assessment; calcitonin rises modestly in pregnancy and must be interpreted in context.

Pediatric MTC (MEN2 prophylactic surgery): referred to high-volume pediatric endocrine surgery centers. Recurrent laryngeal nerve injury and permanent hypoparathyroidism rates are higher in young children; experienced surgeons matter.

Elderly with sporadic MTC: consider tumor biology and comorbidity; some elderly patients with low-burden, slowly-doubling disease can be observed for extended periods.

Pearls and Pitfalls

Pearl: Always Test Pheochromocytoma Before Thyroid Surgery

In any MEN2 carrier and any patient with MTC and family history, plasma free metanephrines and 24-hour urine fractionated metanephrines must be measured and reviewed BEFORE thyroidectomy. An unrecognized pheochromocytoma can cause fatal hypertensive crisis under anesthesia. If pheochromocytoma is found, it is resected first with appropriate preoperative alpha-blockade (phenoxybenzamine or doxazosin) followed by beta-blocker, and only then is the thyroidectomy performed.

Pitfall: Treating MTC with Radioactive Iodine

MTC C-cells do not concentrate iodine. Radioactive iodine ablation has no role in MTC management — neither for adjuvant ablation nor for distant metastases. Treating MTC patients with I-131 is a recognized error that wastes time and exposes the patient to unnecessary radiation. Total thyroidectomy with appropriate central and lateral neck dissection is the curative modality; systemic therapy is RET-selective TKI for advanced disease.

Pearl: Test RET Germline in All MTC Patients

All patients with MTC should undergo germline RET sequencing — not just those with family history. Approximately 5–10% of patients without known family history will be found to carry germline RET mutations (especially de novo MEN2B M918T mutations, which represent 50% of MEN2B cases). Identification triggers cascade family testing that can save first-degree relatives through prophylactic thyroidectomy.

Pitfall: TSH Suppression in MTC

Unlike differentiated thyroid cancer, MTC is not TSH-responsive — C-cells lack TSH receptors. Suppressing TSH below normal range provides no oncologic benefit and exposes the patient to unnecessary cardiovascular and bone risks of subclinical hyperthyroidism. The levothyroxine target is mid-normal TSH (typically 0.5–2.5 mIU/L). Apply suppression only if a coexistent differentiated thyroid cancer is also present.

Frequently Asked Questions

Why does medullary thyroid cancer not respond to radioactive iodine?
Medullary thyroid cancer arises from parafollicular C-cells, which are derived from neural crest and do not express the sodium-iodide symporter (NIS) — the membrane transporter that allows follicular thyroid cells to concentrate iodine. Without NIS, MTC cells cannot accumulate radioactive iodine, so I-131 ablation has no therapeutic effect. This is why surgical removal of all macroscopic tumor is the cornerstone of curative therapy and why advanced disease requires RET-selective tyrosine kinase inhibitors rather than radioiodine.
What is the role of calcitonin in MTC diagnosis and surveillance?
Calcitonin is produced by parafollicular C-cells and is highly elevated in nearly all clinically apparent MTC. It serves three roles: diagnostic (basal levels above 100 pg/mL strongly suggest MTC; FNA washout calcitonin enhances cytology sensitivity), prognostic (postoperative calcitonin doubling time correlates with survival — doubling less than 6 months indicates aggressive disease), and surveillance (every 3–12 months postoperatively, with rising trends triggering imaging and systemic therapy decisions). Calcitonin should be measured alongside CEA, since dedifferentiation can produce divergent biomarker patterns.
When should prophylactic thyroidectomy be performed in MEN2 carriers?
Timing depends on RET mutation risk category per ATA 2015 guidelines. Highest-risk mutations (M918T, MEN2B) require thyroidectomy within the first year of life — ideally by 6 months. High-risk mutations (codon C634, A883F, classic MEN2A) require thyroidectomy before age 5. Moderate-risk mutations may be managed with thyroidectomy by age 5 or with annual calcitonin and ultrasound surveillance, deferring surgery until calcitonin elevation or imaging abnormality. Pheochromocytoma must always be excluded biochemically before surgery, and surgery should be performed at a high-volume pediatric endocrine surgery center.
What are selpercatinib and pralsetinib in MTC therapy?
Selpercatinib (Retevmo) and pralsetinib (Gavreto) are highly selective RET kinase inhibitors approved for RET-mutated medullary thyroid cancer. Selpercatinib is dosed 160 mg orally twice daily (120 mg if weight under 50 kg); pralsetinib is 400 mg orally once daily on empty stomach. Both achieve objective response rates of 60 to 73 percent and durable disease control, representing a paradigm shift from earlier multi-targeted TKIs vandetanib and cabozantinib (which had higher toxicity and lower response rates). Treatment continues until progression or unacceptable toxicity. Common toxicities include hypertension, transaminitis, QTc prolongation, and (for pralsetinib) pneumonitis.
What distinguishes MEN2A from MEN2B?
MEN2A combines medullary thyroid cancer (nearly 100 percent penetrance), pheochromocytoma (50 percent), and primary hyperparathyroidism (20 to 30 percent), with mutations clustering at codons C634, C609, C611, C618, C620, and others. MEN2B presents earlier and more aggressively: medullary thyroid cancer often before age 5, pheochromocytoma in 50 percent, mucosal neuromas (tongue, lips, conjunctiva — pathognomonic), marfanoid habitus, and intestinal ganglioneuromatosis; primary hyperparathyroidism is absent. Nearly all MEN2B is caused by the M918T mutation in codon 918. Approximately 50 percent of MEN2B cases are de novo without family history, which is why germline RET testing is mandatory in all MTC patients regardless of family history.
Article published by gomdori, MD · Endocrine Oncology · 2026-10-02
Educational content only — not a substitute for individualized medical care.

Practice Insights — Synthesized Patterns for Medullary Thyroid Cancer Care

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across published practice patterns, clinicians have learned that this rare cancer punishes shortcuts more than any other thyroid malignancy. The four traps experienced clinicians see repeatedly: skipping germline RET testing in “sporadic” cases, operating without pheochromocytoma screening, anchoring on absolute calcitonin instead of doubling time, and reaching for cabozantinib before checking RET status. Below is how they actually run these cases.

RET Germline Testing in EVERY MTC

In practice, every MTC patient — sporadic-appearing or not — gets germline RET sequencing at diagnosis. Roughly 25% of “sporadic” MTC turns out to be germline-positive (occult MEN2A/2B/FMTC), and the implications cascade to cascade family screening, pheochromocytoma surveillance, and prophylactic thyroidectomy for at-risk relatives. The single biggest missed opportunity clinicians have inherited is the index MTC patient whose siblings or children developed advanced MTC because germline testing was never done. A practical rule: RET sequencing is not optional in MTC, ever.

Pheochromocytoma Screen BEFORE Thyroidectomy

The catastrophic preventable event in MEN2 is operating on the thyroid before screening for pheochromocytoma — a catecholamine surge under anesthesia can be lethal. In practice, every newly diagnosed MTC patient — including those with apparently sporadic disease pending germline results — gets plasma free metanephrines drawn before scheduling surgery. If germline RET testing is positive for MEN2A or MEN2B, formal pheochromocytoma evaluation (plasma + 24h urine metanephrines + adrenal imaging) is mandatory pre-op. Pheo, if present, is removed first.

Calcitonin Doubling Time, Not Absolute Value

The reflex to escalate therapy based on an absolute calcitonin number misses the actual prognostic signal. In experienced hands, calcitonin doubling time is the most informative biomarker: doubling time <6 months indicates aggressive disease warranting systemic therapy consideration; >24 months indicates indolent disease where observation is appropriate even with elevated absolute levels. Experienced clinicians track calcitonin q3 months in active disease, plot the doubling time, and document the trajectory at every visit. The patient with calcitonin 800 stable over 4 years is in different territory from the patient with calcitonin 200 doubling every 4 months.

RET-Specific TKI Before Multikinase

The selective RET inhibitors selpercatinib and pralsetinib produce dramatically better response rates and tolerability than the multikinase inhibitors (cabozantinib, vandetanib) in RET-altered MTC — which is roughly 60-70% of advanced disease. In practice, advanced MTC requiring systemic therapy gets RET status confirmed (tissue or ctDNA) before drug selection. RET-positive disease starts on selpercatinib; only RET-negative disease defaults to cabozantinib. The historical “cabozantinib first-line” reflex is outdated and underserves the majority of advanced MTC patients.

Illustrative Scenario — A Case That Defined The RET-Testing Discipline

(Composite teaching scenario assembled from published patterns; not an individual patient.)

A woman in her early 50s had MTC diagnosed and total thyroidectomy with central lymph node dissection 4 years prior at an outside institution; pathology read “sporadic MTC” without germline testing performed. She presented to the clinic for surveillance with rising calcitonin (320 → 580 → 940 pg/mL over 12 months — doubling time approximately 8 months). clinicians ordered germline RET sequencing as the first step — positive for a MEN2A-associated cysteine mutation. The treating clinicians then identified two of her three adult children also carried the mutation; both underwent prophylactic thyroidectomy with C-cell hyperplasia identified, and her brother was diagnosed with early MTC that would have been missed for years. Her own systemic therapy started on selpercatinib (RET-positive); she achieved partial response within 4 months.

The takeaway: every MTC must have germline RET testing, full stop. Her family history would have been “negative” without testing the proband — but the mutation was there from the start and three additional family members benefited from early identification. The 4-year delay in germline testing was the only thing that prevented two of her family members from receiving prophylactic surgery before invasive disease developed.

Practice Pattern Refinements Beyond the Standard Guideline

  1. Germline RET sequencing within 2 weeks of MTC diagnosis. Non-negotiable on the workup checklist. Genetic counseling referral is concurrent. Cost is modest, insurance approval is straightforward with MTC diagnosis, and the cascade screening implications are enormous. clinicians document the result and the cascade family screening plan in the consultation note for every MTC patient.
  2. Plasma metanephrines before any thyroidectomy. Even in “sporadic-appearing” MTC where germline result is pending. The 3-day result delay for germline testing cannot delay surgery, but the metanephrine result returns within 24 hours and rules out the most dangerous intraoperative complication. clinicians will not schedule MTC surgery without this lab in hand.
  3. Calcitonin doubling-time tracker built into the chart. Standardized spreadsheet plotted at every visit — calcitonin and CEA both, with doubling time calculated and displayed. Visit-to-visit trajectory is the decision-driving metric. Seasoned clinicians share the graph with patients during discussions about whether to escalate to systemic therapy; the visual makes the abstract risk concrete and improves shared decision-making.
  4. RET mutation-specific prophylactic surgery timing in MEN2 children. ATA-Highest Risk (M918T MEN2B) — thyroidectomy in the first year of life. ATA-High (specific codon 634 mutations) — by age 5. ATA-Moderate — by adolescence with calcitonin guidance. Experienced practitioners write explicit timing recommendations in the pediatric referral, not generic “follow pediatric endocrine,” because the risk-category timing is poorly known outside specialty centers.
Medullary Thyroid Cancer Framework Four-panel matrix: universal germline RET, pre-op pheo screen, calcitonin doubling time, RET-specific TKI priority. MTC Management Framework Panel 1 — Universal Germline RET “Sporadic MTC” — 25% germline + Family history can be falsely “negative” A practical rule: RET sequencing in EVERY MTC Within 2 wk of diagnosis, concurrent genetic counseling Cascade screen first-degree relatives Identify pre-clinical MEN2 carriers Single biggest missed opportunity in MTC Panel 2 — Pheo Screen Before OR Catastrophe: thyroidectomy with pheo unscreened Anesthesia → catecholamine surge → death pre-op order: Plasma free metanephrines Result in 24h; do NOT operate without If RET (+) MEN2: full pheo workup Plasma + 24h urine + adrenal imaging If pheo present → remove FIRST, thyroid SECOND Panel 3 — Doubling Time > Absolute DT <6 mo DT >24 mo Time → Calcitonin DT <6 mo: aggressive → systemic Tx DT >24 mo: indolent → observe Plot q3 mo on standardized tracker Patient sees the graph during decisions Panel 4 — RET-Specific TKI First Step 1: Confirm RET status Tissue or ctDNA before drug choice RET-altered (~60-70%): Selpercatinib ORR 60-70%, durable, better tolerated RET-negative: Cabozantinib or vandetanib Multikinase — more toxicity, less specific “Cabo first-line” reflex is outdated RET-specific TKI redefines advanced MTC outcomes

Leave a Reply

Your email address will not be published. Required fields are marked *